CJ
ACAD icon

Caitlin John’s Acadia Pharmaceuticals ACAD Stock Holding History

Caitlin John’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$890 Hold
40
– – ﹤0.01% 815
2025
Q4 		$1.07K Sell
40
-35
-47% -$836 ﹤0.01% 789
2025
Q3 		$1.6K Buy
+75
New +$1.77K ﹤0.01% 712
2025
Q1 		– Sell
-75
Closed -$1.38K – 135
2024
Q4 		$1.38K Hold
75
– – ﹤0.01% 701
2024
Q3 		$1.32K Buy
+75
New +$1.25K ﹤0.01% 707

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Caitlin John's ACAD Position: Q1 2026 in Review

Caitlin John held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 40 shares worth $890. The position accounts for ﹤0.01% of the portfolio, ranked #815.

Caitlin John first reported a position in ACAD in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.6K in Q3 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Caitlin John held 40 shares of Acadia Pharmaceuticals worth $890 as of Q1 2026.
  • Caitlin John left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #815 holding.
  • Caitlin John first reported a position in Acadia Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Caitlin John's Acadia Pharmaceuticals position peaked at $1.6K in Q3 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.